As part of our ongoing seminar series, the Centre of Excellence in Severe Asthma hosted A/Prof. Celeste Porsbjerg, for a webinar on “Non-Eosinophilic Asthma: Common but Poorly Understood” on 01 February 2017.
It is now well-recognised that asthma consists of a range of phenotypes. Different patterns of airway inflammation occur in different patients. The inflammatory phenotype effects response to therapy.
Significant progress has been made in our understanding of “eosinophilic” asthma. As a result, several targeted therapies are available for eosinophilic disease. However, non-eosinophilic asthma remains poorly understood.
Non-eosinophilic asthma is common, but disease mechanisms are poorly understood. Several factors have been proposed in non-eosinophilic asthma. These include microbiome, T cell subsets and mast cells. Ion transport in smooth muscle cells may also be altered.
People with non-eosinophilic asthma are less likely to respond to inhaled corticosteroid (ICS) treatment. A/Prof. Porsbjerg raises the question of whether long acting bronchodilators (LABAs) should be considered for add-on therapy instead for this population.
Targeted treatment approaches are required for non-eosinophilic asthma. An improved understanding of the mechanisms underlying disease in this population is required.
About A/Prof. Celeste Porsbjerg:
Celeste Porsbjerg is a Respiratory Specialist and Clinical Research Associate Professor at the Bispebjerg Hospital and University of Copenhagen.
Her research interests revolve around the diagnosis and phenotyping of asthma, with a focus on airway pathophysiology and inflammation. During her Ph.D., she described the usefulness of bronchial provocation testing with mannitol for assessing inflammation driven airway hyperresponsiveness. During her post doc with Professor Peter Gibson’s group in Australia in 2010-11, she described the relationships between airway pathophysiology and subtypes of airway inflammation in older adults with asthma.
Her current research projects are focused on severe asthma, including systematic assessment, phenotyping and biological treatment.